Versant Ventures Chalks Up An IPO At Audentes Therapeutics

Newport Beach-based venture capital ‌investor Versant Ventures can chalk up another IPO this morning, as portfolio company Audentes Therapeutics heads to the NASDAQ Global Market as BOLD. Audentes priced at the midpoint of its earlier, estimate IPO range of $14.00 to $16.00 per share. Versant Ventures had owned 11.1 percent of Audentes Therapeutics before its IPO. Audentes is based in San Francisco.